Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides molecular and other clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 30 patient service centers in New York and New Jersey; and a free-standing STAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. It markets its products and services through its direct sales force and a network of distributors in the United States and internationally. The company was founded in 1976 and is headquartered in New York, New York.

Enzo Biochem, Inc.

For more than 45 years, Enzo Biochem has been a leader in innovation and product development to support a diverse range of needs in biomedical research and healthcare. With a comprehensive portfolio of 20,000 high-quality products including antibodies, genomic probes, assays, biochemicals, and proteins, Enzo supports the work of academic research centers and industry partners who are shaping the future of healthcare around the world. The company’s proprietary products and technologies play central roles in all areas of translational research and drug development, including genomic analysis, protein analysis, cellular analysis, tissue analysis, and small molecule chemistry. Enzo Biochem has a broad and deep intellectual property port-folio, with patent coverage across a number of key enabling technologies.

Enzo Biochem Inc

At Enzo, we’re entering 2024 with our continued commitment to innovation & global science. 

Your trust fuels us on our mission to facilitate research & shape a healthier world.

Your success is our success.
Here's to the groundbreaking discoveries that lie ahead.

#NewYearNewDiscoveries #Science

Enzo Biochem Reports First Quarter Fiscal 2024 Results and Provides Business Update

https://lnkd.in/eHYTQJeY

This Giving Tuesday, Enzo is proud to reaffirm that we are Scientists Enabling Scientists and are committed to supporting the scientific community. 

In the spirit of collaboration and advancement, we're happy to share our continued partnership with New York Institute of Technology (NYIT).

Our donation to NYIT represents a shared vision for scientific progress and innovation.
As we celebrate this day of giving, we're reminded of the impact we can make when we support each other in the pursuit of knowledge and understanding.

Enzo stands committed to empowering educational institutions, researchers, and scientists worldwide, fostering discovery and innovation.

#GivingTuesday #ScienceWithPurpose #EnablingDiscovery #Scientistsenablingscientists

Wishing you a Thanksgiving filled with love and cherished moments. May this holiday season be a time of togetherness and joy. Thank you for trusting us with over 150,000 publications. We are grateful for our customers and partners, who share our relentless pursuit of discovery, and for every breakthrough that brings us closer to a healthier world. 🌎💡

What are you thankful for this year?

We are humbled and honored to receive The Ram’s Horn Award for Corporate Leadership at the Farmingdale State College President’s Gala. We were thrilled to be a part of this great event, which recognized the community spirit and leadership among FSC’s partners, faculty, alumni, and fellow honorees.

In recognition of the many great accomplishments of Farmingdale State College, and in support of our partnership, we are happy to award a $50,000 technology donation. This demonstrates our continued commitment to supporting scientific education and innovation at FSC and within the Long Island Community.

Our thanks again to Farmingdale State College for this prestigious recognition, and for fostering an environment that advances education in our community. We look forward to continued collaboration and achievements through our partnership in the future.

Enzo Biochem Reports Fourth Quarter and Fiscal Year 2023 Results and Provides Business Update

https://lnkd.in/eJZCHfCW

Steven J. Pully Appointed to Enzo Biochem’s Board of Directors

https://lnkd.in/e-6_VSED

Enzo Biochem Announces Departure of Hamid Erfanian and Appointment of Kara Cannon as Interim CEO

https://lnkd.in/eqxxCKAm

Enzo Biochem Completes Sale of Clinical Laboratory to Labcorp

https://lnkd.in/g5iVARAb

msh id	COM:ENZO
symbol	ENZ
name	Enzo Biochem, Inc.
homepage url	https://www.enzo.com
country	US
sector	Healthcare
industry	Medical - Diagnostics & Research
market	STOCKS
employee count	179
crunchbase url	-
linkedin url	-
founders	-

market cap	55.57M
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	-0.59
growth cost of revenue	-0.7
growth depreciation and amortization	-0.41
growth ebitda	-0.11
growth ebitda ratio	-2.81
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-0.49
growth gross profit	-0.72
growth gross profit ratio	-0.05

COM:ENZO

Enzo Biochem

Last Close

0.99

21/11 21:00

Market Cap

55.57M

Beta: -

Volume Today

162.17K

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	50.6M
cost of revenue	50.6M
depreciation and amortization	2.68M
ebitda	-12.12M
ebitda ratio	-0.39
eps	-0.76
eps diluted	-0.76
operating expenses	31.11M
operating income	-24.74M
operating income ratio	-0.8

accounts receivables	5.03M
capital expenditure	-2.76M
cash at beginning of period	22.6M
cash at end of period	83.37M
inventory	7.94M
working capital ttm	59.17M

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-